Anish Suri - 03 Oct 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: PRESIDENT AND CSO
Signature: /s/ Anish Suri by Colin Sandercock, attorney-in-fact
Issuer symbol: CUE
Transactions as of: 03 Oct 2021
Net transactions value: -$183,318
Form type: 4
Filing time: 08 Oct 2021, 16:00:14 UTC
Previous filing: 27 Sep 2021
Next filing: 15 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Options Exercise		+33,334	+45%		108,172	03 Oct 2021	Direct	F1
transaction	CUE	Common Stock	Tax liability	$183,318	-14,134	-13%	$12.97	94,038	06 Oct 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Restricted Stock Units	Options Exercise	$0	-33,334	-100%	$0.000000^*	0	03 Oct 2021	Common Stock	33,334		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3	On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019.